PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Honours Acino Pharma for Pioneering Best Practices in the Pharmaceutical Drug Delivery Space - The improved product formulations based on Acino’s proprietary technology platforms enhance product performance and patient compliance - /
Frost & Sullivan Honours Acino Pharma for Pioneering Best Practices in the Pharmaceutical Drug Delivery Space


NewswireToday - /newswire/ - London, United Kingdom, 2014/11/06 - The improved product formulations based on Acino’s proprietary technology platforms enhance product performance and patient compliance - /

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Based on its recent analysis of the pharmaceutical drug delivery industry, Frost & Sullivan recognizes Acino Pharma AG with the 2014 Europe Frost & Sullivan Award for Enabling Technology Leadership. Acino’s expertise in targeted drug release profiles and strong technical know-how in pellet-coating, transdermal therapeutic patches and biodegradable implants has made it the preferred vendor in contract manufacturing. It has also exhibited considerable skill in developing and manufacturing ‘difficult to produce’ solid oral dosage forms and transdermal systems.

Acino’s products tick the top five purchase factors of highest efficacy, Swiss quality standards, well-proven active ingredients, advanced drug delivery formulations and enhanced quality of lives for patients. Beyond that it is one of the very few global pharmaceutical companies with a comprehensive product portfolio in the malaria therapeutic segment, leveraging therapies that have been in existence over 20 years. Furthermore, it caters to the diverse requirements of local populations from endemic countries as well as those travelling to infected countries.

Acino has extensive experience with pellet-based systems, wherein free-flowing pellets can be filled into capsules or alternatively, combined with suitable excipients and pressed into tablets to form multiple unit particulate systems (MUPS) tablets. Its innovative technologies have also enabled the creation of rapidly dissolving oral disintegrating tablets (ODTs) and pellets in stick packs.

“The company employs active pharmaceutical ingredients to form innovative MUPS for supply to leading European generic companies,” said Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. “The oral dispersible forms are also suited for active ingredients with a high first-pass effect and facilitate the rapid onset of action because of their quick dissolution”

Meanwhile, Acino’s transdermal and topical therapeutic patches ensure prolonged, systemic blood levels of active pharmaceutical ingredients. Its patches are specially designed, fabricated with multiple layers including a backing film, one or more drug incorporating layers (the adhesive system) and a release liner, which is removed before application. In Europe, Acino is the second largest manufacturer of transdermal systems.

Acino also has distinct biodegradable subcutaneous drug implants that facilitate reliable, extended release of the drug over a period of one to six months, minimising the burst phenomenon. Its success in developing, manufacturing and filing transdermal patches and biodegradable implants can be amongst others be attributed to its intelligent selection of suitable materials (films, polymers, absorption enhancers) to optimise formulations.

The company’s strong proprietary product portfolio of oral dose formulations, transdermal formulations and parenterals caters to many therapeutic markets ranging from analgesics and anti-infectives to chronic diseases. These technologies are particularly useful in innovator/branded drug reformulations, as they can be pursued under the 505(b)(2) regulatory pathway for faster, lower-cost product development with higher approval probability.

“Acino, with its proprietary transdermal delivery systems and ODTs is best positioned to target a wide patient population, including geriatric, paediatric, as well as adults and adolescents with swallowing difficulty,” said Frost & Sullivan Senior Research Analyst Aiswariya Chidambaram. “Its technology expertise and innovation have set it apart in the industry and will allow Acino to further expand on its market share.”

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products but also enables the development of newer products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Acino
Acino (, a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand “Acino Switzerland”, Acino markets Swiss-quality medicines in up and coming economies, currently 80 countries in the Middle East, Africa, Latin America and Asia. The Acino Group is headquartered in Aesch BL. On December 12, 2013, Pharma Strategy Partners GmbH, a wholly-owned subsidiary of Avista Capital Partners and Nordic Capital, successfully completed its public tender offer for Acino Holding AG.

About Frost & Sullivan
Frost & Sullivan (, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation

Contact: Kalle Känd - Chief Commercial Officer Acino Group
T: +41(0)61 338 6056 - E: kalle.kaend[.]

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Frost & Sullivan


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Frost & Sullivan Honours Acino Pharma for Pioneering Best Practices in the Pharmaceutical Drug Delivery Space

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan | Acino Pharma
Publisher Contact: Adelaide Mendes - 
+44(0)20 7915 7869 adelaide.mendes[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Frost & Sullivan / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  La Bella Bakery Artisan Bakery Arizona


  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (